China Startup CirCode Gets Clearance for Trial of Circular RNA Therapy

Why It Matters

The FDA nod validates circular RNA as a viable therapeutic platform and signals growing regulatory openness to Chinese innovators entering the U.S. market, potentially accelerating global RNA‑drug development.

Key Takeaways

• FDA grants IND for circular RNA therapy
• First Chinese biotech to secure US trial clearance
• Circular RNA offers stable protein expression
• Potential for vaccines and rare disease treatments
• Market interest grows in next‑gen RNA therapeutics

Pulse Analysis

Circular RNA represents a next‑generation leap in nucleic‑acid therapeutics. Unlike linear messenger RNA, circular RNA forms a covalently closed loop that resists exonuclease degradation, enabling prolonged protein production from a single dose. Researchers can engineer these molecules to self‑splice, eliminating the need for a 5' cap or poly‑A tail, which simplifies manufacturing and reduces immunogenicity. The technology promises more efficient delivery of therapeutic proteins, opening doors for treatments that require sustained expression, such as enzyme replacement or vaccine antigens.

The FDA’s IND approval for Cir‑Code’s candidate is a watershed moment for both the modality and cross‑border biotech collaboration. Historically, Chinese firms have faced steep regulatory hurdles in the United States, often requiring joint ventures or U.S. subsidiaries. By obtaining direct clearance, Cir‑Code demonstrates that rigorous preclinical data and robust quality systems can meet FDA standards, encouraging other Chinese innovators to pursue U.S. trials. This regulatory breakthrough may also prompt the FDA to refine its guidance on circular RNA, fostering a clearer pathway for future submissions.

Investor appetite for RNA‑based platforms has surged since the COVID‑19 vaccine rollout, and circular RNA is quickly becoming the next focal point. Analysts project that the global RNA therapeutics market could exceed $30 billion by 2030, with circular RNA poised to capture a meaningful share due to its stability and manufacturing advantages. However, challenges remain, including scalable production, precise control of circularization efficiency, and long‑term safety profiling. Successful trial outcomes from Cir‑Code could de‑risk the space, catalyze strategic partnerships, and accelerate funding for a broader pipeline of circular RNA medicines targeting rare diseases, oncology, and infectious diseases.